About Nascent polypeptide-associated complex subunit alpha, muscle-specific form
Nascent polypeptide-associated complex subunit alpha, muscle-specific form (NACA) is a protein
from Homo sapiens identified by UniProt accession
E9PAV3, 2078 residues long.
MolForge cross-references it against 0 known binders and
185 disease associations.
Target properties
| Protein name | Nascent polypeptide-associated complex subunit alpha, muscle-specific form |
|---|
| UniProt accession | E9PAV3 |
|---|
| Gene | NACA |
|---|
| Organism | Homo sapiens |
|---|
| Length | 2078 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (185)
Diseases linked to this target (Open Targets).
- diastolic blood pressure · score 0.27
- mean platelet volume · score 0.21
- hepatocellular carcinoma · score 0.19
- multiple myeloma · score 0.19
- gastric carcinoma · score 0.18
- T-cell acute lymphoblastic leukemia · score 0.18
- clear cell renal carcinoma · score 0.18
- breast carcinoma · score 0.18
- head and neck squamous cell carcinoma · score 0.18
- acute myeloid leukemia · score 0.18
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-E9PAV3-F1 | alphafold | PREDICTED | 37.72 | — |
Amino-acid sequence (2078 residues)
MPGEATETVP ATEQELPQPQ AETAVLPMSS ALSVTAALGQ PGPTLPPPCS PAPQQCPLSA ANQASPFPSP STIASTPLEV PFPQSSSGTA LPLGTAPEAP TFLPNLIGPP ISPAALALAS PMIAPTLKGT PSSSAPLALV ALAPHSVQKS SAFPPNLLTS PPSVAVAESG SVITLSAPIA PSEPKTNLNK VPSEVVPNPK GTPSPPCIVS TVPYHCVTPM ASIQSGVASL PQTTPTTTLA IASPQVKDTT ISSVLISPQN PGSLSLKGPV SPPAALSLST QSLPVVTSSQ KTAGPNTPPD FPISLGSHLA PLHQSSFGSV QLLGQTGPSA LSDPTVKTIS VDHSSTGASY PSQRSVIPPL PSRNEVVPAT VAAFPVVAPS VDKGPSTISS ITCSPSGSLN VATSFSLSPT TSLILKSSPN ATYHYPLVAQ MPVSSVGTTP LVVTNPCTIA AAPTTTFEVA TCVSPPMSSG PISNIEPTSP AALVMAPVAP KEPSTQVATT LRIPVSPPLP DPEDLKNLPS SVLVKFPTQK DLQTVPASLE GAPFSPAQAG LTTKKDPTVL PLVQAAPKNS PSFQSTSSSP EIPLSPEATL AKKSLGEPLP IGKPASSMTS PLGVNSSASV IKTDSYAGPD SAGPLLKSSL ITPTVAAFPL ESADPAGVAP TTAKGTSTYT TTASPFLEGT VSLAPKNHPV KEGTLTTLPL VPTASENCPV APSPQNTCAP LATLVLAPEI PKSVPSPSLP PAGTPPGTKK VDGISHTSAL APVASSPKEC PTEDSGASAT ASSKGTLTYL ADSPSPLGVS VSPQTKRPPT KKGSAGPDTP IGNLSSPVSP VEASFLPENS LSFQGSKDSP ATTHSPTPPS PKGAPTPSAV TPLSPKGVTL PPKETPTPSV VNLPFPKEGP ATPAPKQAPA LSMTSSSPKK ARATPAPKGI PASPSPKGAP TPPAATPPSP KGGPATPSPK WAPTPPAATP PSPKGGPATP SPKGAPTPPA ATPPSPKGGP ATPSPKGAPT PPAVTPPSPK GSPAATPFPK GASTPPAATP PSPKGSPAAT PLPKGAPTTP AATLPSPKGG PATPSLKGAP TPPAATPPSP KGGPATPSPK GAPMPPAATP PSPKGGLATP PHKGAPTTPA ATPPSPKGGL ATPPPKGAPT TPAATPPSPK GGLATPPPKG APTTPAATPP SPKGGLATPS PKGAPTTPAA TPPSPKGGLA TPSPKGAPTT PAATPPSPKG GLATPSPKGA PTTPAATPPS PKGGPATPPP KGAPTPPAAT PPSLKGGLAT PPHKGAPNPA VVTPPSPKGG PATSPPKGAP TPPAATPPSP KGSPGTPPPK GAPTPPAVTP PSPKGTPTLP ATTPSSKGGP TTPSSKEGPT PPAATPSHKG GPAMTPPSPK RGPAIPSPKG DPTSPAVIPL SPKKAPATPV TREGAATPSK GDLTPPAVTP VSLKKAPATS APKGGPATPS SKGDPTLPAV TPPSPKEPPA PKQVATSSSP KKAPATPAPM GAPTLPAVIP SSPKEVPATP SSRRDPIAPT ATLLSKKTPA TLAPKEALIP PAMTVPSPKK TPAIPTPKEA PATPSSKEAS SPPAVTPSTY KGAPSPKELL IPPAVTSPSP KEAPTPPAVT PPSPEKGPAT PAPKGTPTSP PVTPSSLKDS PTSPASVTCK MGATVPQASK GLPAKKGPTA LKEVLVAPAP ESTPIITAPT RKGPQTKKSS ATSPPICPDP SAKNGSKGPL STVAPAPLLP VQKDSSKTAK GKDASHSPKG PLAPPESKAS TPLTAAAFEK VLPKPESASV SAAPSPPVSL PLAPSPVPTL PPKQQFLPSS PGLVLESPSK PLAPADEDEL LPLIPPEPIS GGVPFQSVLV NMPTPKSAGI PVPTPSAKQP VTKNNKGSGT ESDSDESVPE LEEQDSTQAT TQQAQLAAAA EIDEEPVSKA KQSRSEKKAR KAMSKLGLRQ VTGVTRVTIR KSKNILFVIT KPDVYKSPAS DTYIVFGEAK IEDLSQQAQL AAAEKFKVQG EAVSNIQENT QTPTVQEESE EEEVDETGVE VKDIELVMSQ ANVSRAKAVR ALKNNSNDIV NAIMELTM
Explore Nascent polypeptide-associated complex subunit alpha, muscle-specific form with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets